It is generally contraindicated for pregnant or nursing women, and patients with active malignancies should consult their oncologist before starting any peptide therapy
Fecal microbiota transplantation and replenishment of short-chain fatty acids protect against chronic cerebral hypoperfusion-induced colonic dysfunction by regulating gut microbiota, differentiation of Th17 cells, and mitochondrial energy metabolism
In addition, BPC 157 fights medical conditions such as leaky gut, IBS, cramps in the intestines, and Crohns disease by simultaneously working in the digestive tract
Plasma half-life: Approximately 30 minutes following systemic uptake, similar to injectable administration
This peptide combination is formulatedstrictly for laboratory, analytical, and educational research purposes only